|
Jul 15
|
Aclaris Therapeutics Begins Phase 1 Clinical Trial for Bispecific Antibody ATI-052 Targeting Inflammatory Diseases
|
|
Jun 30
|
Aclaris Therapeutics Added to the Russell 2000® and Russell 3000® Indexes
|
|
Jun 26
|
Aclaris Therapeutics to Participate in the H.C. Wainwright Inflammation & Immunology Virtual Conference
|
|
Jun 23
|
Aclaris Therapeutics Initiates Phase 1a/1b Program for its Novel Bispecific Antibody ATI-052
|
|
Jun 2
|
Aclaris Therapeutics Initiates Phase 2 Trial of Bosakitug (ATI-045) in Atopic Dermatitis
|
|
Feb 27
|
Aclaris Therapeutics (ACRS) Reports Q4 Loss, Tops Revenue Estimates
|
|
Feb 27
|
Aclaris: Q4 Earnings Snapshot
|
|
Feb 27
|
Aclaris Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Corporate Update
|
|
Feb 12
|
New Publication Highlights Unique Properties of ATI-2138, a Potent and Selective Inhibitor of ITK and JAK3
|
|
Jan 30
|
Aclaris Therapeutics Announces Formation of New Scientific Advisory Board
|
|
Nov 26
|
Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference
|
|
Nov 22
|
Aclaris Therapeutics And 2 Other US Penny Stocks To Watch
|
|
Nov 6
|
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates
|
|
Nov 6
|
Aclaris: Q3 Earnings Snapshot
|
|
Nov 6
|
Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
|
|
Oct 9
|
Millennium Management LLC Reduces Stake in Aclaris Therapeutics Inc
|
|
Oct 8
|
Is BellRing Brands (BRBR) Stock Outpacing Its Medical Peers This Year?
|
|
Jun 6
|
Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
|
|
May 10
|
Earnings Update: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Just Reported And Analysts Are Boosting Their Estimates
|
|
May 8
|
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript
|